A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Capecitabine|DRUG: Exemestane|DRUG: Everolimus
Sponsor: Novartis Pharmaceuticals